# AstraZeneca Plc Lynparza receives positive EU CHMP opinion

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-lynparza-receives-positive-eu-chmp-opinion/412768429
- Published: 2019-03-01T14:01:56+00:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US
and Canada) today announced that the Committee for Medicinal Products for Human 
Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending
the use of Lynparza (olaparib) tablets as monotherapy for the treatment of adult
patients with germline BRCA1/2-mutations, who have human epidermal growth factor
receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.

Patients should have previously been treated with an anthracycline and a taxane 
in the (neo)adjuvant or metastatic setting unless patients were not suitable for
these treatments. Patients with hormone receptor (HR)-positive breast cancer should
also have progressed on or after prior endocrine therapy, or be considered unsuitable
for endocrine therapy.

> **Dave Fredrickson, Executive Vice President, Oncology, said:** “Despite progress
> in treating patients with advanced breast cancer, there remains a significant 
> unmet need for new treatment options. If approved, Lynparza will provide these
> patients with both a targeted and oral chemotherapy-free option. We now have evidence
> supporting the potential use of Lynparza in patients with BRCA-mutated breast,
> ovarian and pancreatic cancers, which demonstrates our ongoing commitment to improving
> patient outcomes in difficult-to-treat cancers.”
> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, Merck Research Laboratories, said:** “The positive opinion from
> CHMP for Lynparza in this patient population is an important milestone. This decision
> brings us one step closer to offering a new treatment option to patients with 
> advanced breast cancer and further underscores the critical need to identify patients’
> BRCA status, in addition to hormone receptor and HER2 expression status, as part
> of the management of this disease.”

The positive opinion is based on data from the randomised, open-label, Phase III
OlympiAD trial, which tested Lynparza against the physician’s choice of chemotherapy.

Lynparza is currently approved in over 60 countries including those in the EU for
the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless
of BRCA status. It is approved in the US for 1st-line maintenance therapy in BRCAm
advanced ovarian cancer following response to platinum-based chemotherapy. It is
also approved in several countries, including the US and Japan, for germline BRCAm
HER2-negative metastatic breast cancer previously treated with chemotherapy; regulatory
reviews are underway in other jurisdictions.

Share on:
